News brief
On 2026-08-18, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Sichuan Shengchengguozhuanhua Investment Yindao Fund Partnership (Limited Partnership), Chengdu Hongsheng Phase One Venture Capital Partnership (Limited Partnership), Wuxi City Biotechnology Pharmaceutical Industry Fund (Limited Partnership), Shenzhen City Pengyuanjishi Private Equity Investment Fund Partnership (Limited Partnership), Chengdu Weilai Industry Venture Capital Development Fund Partnership (Limited Partnership), Shanghai Dingtaixing Technology Development Co., Ltd.. The company is a developer of chemically induced cell therapy drugs.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年8月18日，据烯牛数据报道，睿健医药完成股权投资融资，金额未披露。投资方为四川省成果转化投资引导基金合伙企业（有限合伙），成都弘生一期创业投资合伙企业（有限合伙），无锡市生物医药产业基金（有限合伙），深圳市鹏远基石私募股权投资基金合伙企业（有限合伙），成都未来产业创业投资发展基金合伙企业（有限合伙），上海鼎泰星科技发展有限公司。该公司为化学诱导细胞治疗药物研发商。